Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Radiopharm TheranosticsRADX -1.42%33 PS Ratio is 5.88 as of Sep. 09, 2026, which is 76% below its 10-year median of 25.00. GuruFocus rates RADX with a GF Score™ of 33/100 and a GF Value™ of $2.34 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 936 Biotechnology companies, Radiopharm Theranostics ranks better than 69.87% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Radiopharm Theranostics's share price is $2.08.
Radiopharm Theranostics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2025 was $0.35. Hence, Radiopharm Theranostics's PS Ratio for today is 5.88.
The historical rank and industry rank for Radiopharm Theranostics's PS Ratio or its related term are showing as below:
RADX'
s PS Ratio Range Over the Past 10 Years
Min: 4.37 Med: 25 Max: 127.5
Current: 4.43
During the past 5 years, Radiopharm Theranostics's highest PS Ratio was 127.50. The lowest was 4.37. And the median was 25.00.
RADX's PS Ratio is ranked better than 69.87% of 936
companies
in the Biotechnology industry
Industry Median: 9.52
vs RADX: 4.43
Radiopharm Theranostics (NAS:RADX) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Radiopharm Theranostics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Radiopharm Theranostics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Radiopharm Theranostics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Radiopharm Theranostics's Share Price of today is $2.08.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Radiopharm Theranostics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2025 was $0.35.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Radiopharm Theranostics (RADX) has a PS Ratio of 5.88 as of Sep. 09, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Radiopharm Theranostics and its competitors. This is 76% below median its historical median of 25.00. Over the past decade, Radiopharm Theranostics' PS Ratio has ranged from 4.37 to 127.50. According to the industry distribution chart, Radiopharm Theranostics ranks #282 out of 936 companies in the Biotechnology industry, placing it in the top 30.1%.
Is Radiopharm Theranostics' PS Ratio too high?
Radiopharm Theranostics' current PS Ratio of 5.88 is 76% below median its 10-year median of 25.00. Over the past 10 years, this metric has ranged from a low of 4.37 to a high of 127.50. The Biotechnology industry median PS Ratio is 9.52. Radiopharm Theranostics' value of 5.88 is 38.2% below this industry median. Based on the distribution chart, Radiopharm Theranostics ranks #282 out of 936 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Radiopharm Theranostics has a GF Score™ of 33/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Radiopharm Theranostics' PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Radiopharm Theranostics ranks #282 out of 936 companies for PS Ratio. This puts Radiopharm Theranostics in the upper half of its industry. The industry median PS Ratio is 9.52. Radiopharm Theranostics' value of 5.88 is 38.2% below this benchmark. Historically, Radiopharm Theranostics' own PS Ratio has ranged from 4.37 to 127.50 over the past decade. While the company's 10-year median is 25.00 vs. the industry median of 9.52, Radiopharm Theranostics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.52, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Radiopharm Theranostics's current PS Ratio of 5.88 is 38.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Radiopharm Theranostics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Radiopharm Theranostics's current PS Ratio is 5.88, which is 76% below median its own 10-year median of 25.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radiopharm Theranostics stock overvalued right now?
Based on GuruFocus' analysis, Radiopharm Theranostics (RADX) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.34, compared to a current price of $2.08 — trading 11.1% below its estimated fair value. The current PS Ratio is 5.88, which is 76% below median its 10-year median of 25.00 and 38.2% below the Biotechnology industry median of 9.52. Radiopharm Theranostics' overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Radiopharm Theranostics (RADX), the current PS Ratio is 5.88 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Radiopharm Theranostics (RADX) Overvalued in 2026?
Based on GuruFocus' analysis, Radiopharm Theranostics stock appears to be undervalued.
The current stock price of $2.08 is trading 11.1% below its estimated GF Value™ of $2.34.
GuruFocus considers Radiopharm Theranostics to be Modestly Undervalued.
Key valuation signals for RADX:
PS Ratio: 5.88 (76% below median its 10-year median of 25.00)
GF Value™: $2.34 vs. price of $2.08 (11.1% below fair value)
Industry Position: 38.2% below the Biotechnology median (#282 of 936)
No single metric tells the full story. See the RADX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.
33GF Score
Get the complete analysis for RADX
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RADX has been successfully added to your 
